AbstractAimWith diabetes comes a significant risk of macrovascular and microvascular complications. Circulating aldosterone levels increase in patients with diabetes. Aldosterone can directly affect vascular function via activation of the mineralocorticoid receptor (MR). We hypothesized that aldosterone via endothelial MR impairs endothelial function in a murine model of experimental diabetes.MethodEndothelial cell‐specific mineralocorticoid receptor knockout MR^flox/flox; Tie2‐Cre mice (ECMR‐KO) and wild‐type FVB littermates were subjected to an experimental type‐1 diabetic model by low dose streptozotocin injections (55mg/kg/day) for five consecutive days. After 10 weeks of diabetes, second‐order mesenteric resistance arteries were perfused ex vivo to evaluate vessel contractility and endothelial function. The effect of ex vivo incubation with aldosterone with and without the antagonist, spironolactone was determined.ResultsDiabetic ECMR‐KO and wild‐type mice had similar, elevated, plasma aldosterone concentration while only diabetic wild‐type mice displayed elevated urine albumin excretion and cardiac and kidney hypertrophy at 10 weeks. There were no differences in contraction (Emax and EC₅₀) to thromboxane receptor agonist (U46619) and elevated K⁺ between groups. Wild‐type diabetic mice showed impaired acetylcholine (ACh)‐dependent relaxation, while diabetic ECMR‐KO mice had intact ACh‐mediated relaxation. Aldosterone incubation ex vivo impaired ACh mediated relaxation and rendered responses similar to diabetic WT arteries. Direct, ex vivo aldosterone effects were absent in ECMR‐KO animals. Ex vivo inhibitory effects of aldosterone on endothelial relaxation in arteries from WT were abolished by spironolactone.ConclusionThese findings show that endothelial cell mineralocorticoid receptor activation accounts for diabetes‐induced systemic endothelial dysfunction in experimental diabetes and may explain the cardiovascular protection by MR antagonists in diabetes.